China’s Dominance in East Asia Oxytocin Industry Surges to Accelerate at a 6.2% CAGR by 2030 | FMI

Oxytocin Industry
Oxytocin Industry

China continues to assert its dominance in the East Asia Oxytocin industry, capturing a substantial 67.3% share in 2021, with projections indicating a robust compound annual growth rate (CAGR) of 6.2% during the forecast period.

The surge in the Oxytocin industry in China is directly linked to the country’s escalating investment and advancements in automation and robotic assistive devices. China stands out as the primary contributor to the development industry for robotic devices, catering to diverse applications, including Oxytocin administration for orthopedic procedures.

The growth is notably attributed to China’s role as a global manufacturing hub, leading to an increasing demand trend over the forecast period. As the country continues to innovate and enhance its capabilities in robotic technologies, the Oxytocin industry is expected to witness substantial expansion.

Get your Sample Report with Latest Market Information!
https://www.futuremarketinsights.com/reports/sample/rep-gb-11218

Births are happening more frequently, but there are also more challenges for women to deal with. Over 50,000 women are thought to experience life-threatening problems nationwide, according to the Centres for Disease Control and Prevention.

Consequently, healthcare providers are incorporating solutions aimed at reducing trauma faced by patients which include numerous approaches. A common complication faced by women is postpartum hemorrhage, for which oxytocin treatment is a highly preferred option. A value CAGR exceeding 8% is projected for the market through 2030.

Key Takeaways:

  • Postpartum hemorrhage (PPH) solutions to comprise nearly 90% of the revenue share in 2020 by product type
  • Hospital pharmacies remain key distribution channels, online pharmacies’ popularity to widen
  • Opportunities abound across the Middle East & Africa (MEA) owing to rising PPH incidence in Africa
  • Global oxytocin market is projected to reach US$ nearly US$ 165 Mn by 2030

“Government initiatives to promote women and children’s health are bolstering global efforts to improve maternity care across healthcare settings, thereby opening significant growth avenues for the global oxytocin market,” comments the FMI analyst.

Get The Information You Need By Connecting With Our Analyst Today! https://www.futuremarketinsights.com/ask-question/rep-gb-11218

Therefore, efforts are being made towards ensuring adequate and proper treatment to pregnant women across all regions. Furthermore, oxytocin has also been touted as an effective anti-viral agent, thus raising optimism that it could be effectively leveraged to promote drug or vaccine development.

The National Center for Biotechnology Information hypothesizes that oxytocin contains dipeptidyl peptidase-4 (DPP4) protease inhibitors could be effective against the existing novel coronavirus strain. It further propagates that enhancing endogenous oxytocin levels could increase viral resistance and improve health of vulnerable groups.

Competitive Landscape Oxytocin Industry:

  • Pfizer Inc.
  • Novartis AG
  • Ferring B.V.
  • Fresenius Kabi LLC
  • Hikma Pharmaceuticals PLC
  • Endo International plc. (Par Sterile Products, LLC)
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Yuhan Corporation

The market is highly fragmented, peppered with numerous regional and global level market players. These players largely concentrate on forging strategic collaborations with existing players, regional distributors, product launches and acquisitions. Most players are concentrating on offering anesthetic oxytocin solutions to reduce labor induced complications for C-section operations.

Ignite Innovation with Customization: Uncover the Possibilities in Our Report! https://www.futuremarketinsights.com/customization-available/rep-gb-11218

Key Market Segments Covered in Oxytocin Industry Research:

By Product:

  • Antepartum
  • Postpartum

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Ronak Shah

Associate Vice President at Future Market Insights is deeply committed to uncovering actionable insights for consumer and food and beverage players. She brings a unique blend of analysis, industry trends, and consumer behavior to put data into perspective.

What she makes out of data becomes a delight to read. She has authored many opinions, including for publications like Process Industry Informer and Spinal Surgery News, as she understands the market pulse and consumers' shifting preferences.

She likes to bring experts to a roundtable to weigh the impact of a trend on an industry. Catch up with her discussion on the impact of AI in packaging.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these